- Home
- HCAI vs BOLT Comparison
HCAI vs BOLT Comparison
Compare HCAI & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCAI | BOLT |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.1M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HCAI | BOLT |
|---|---|---|
| Price | $0.53 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | ★ 758.7K | 31.2K |
| Earning Date | 05-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,525.07 |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.13 | $3.10 |
| 52 Week High | $25.99 | $7.20 |
Technical Indicators
Market Signals| Indicator | HCAI | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 15.13 | 47.24 |
| Support Level | $0.49 | $3.13 |
| Resistance Level | $0.74 | $4.34 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 2.28 | 40.48 |
Price Performance
Historical ComparisonAbout HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.